NCT02077699View on ClinicalTrials.gov

Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Irritable Bowel Syndrome
Interventions
DIETARY_SUPPLEMENT

Lactobacillus casei DG

Lactobacillus casei DG (24 billion of live cells per pill) - 2 pills b.i.d. for 4 weeks

Trial Locations (1)

00133

UOC di Gastroenterologia - Policlinico Tor Vergata, Roma

All Listed Sponsors
lead

SOFAR S.p.A.

INDUSTRY

NCT02077699 - Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study | Biotech Hunter | Biotech Hunter